Pomerantz Investigates Aardvark Therapeutics Securities Fraud
Analysis based on 11 articles · First reported May 21, 2026 · Last updated May 26, 2026
The market is negatively impacted by the significant stock price decline of MiNK Therapeutics, which fell 56.2% and then 32.1% following the pause and clinical hold on its ARD-101 trial. This event signals increased risk for investors in the pharmaceutical sector, particularly those involved in drug development, and highlights the regulatory scrutiny by the United States — Food and Drug Administration.
Pomerantz LLP is investigating MiNK Therapeutics for securities fraud after the company's stock price plummeted following two major announcements. On February 27, 2026, MiNK Therapeutics voluntarily paused its Phase 3 HERO trial for ARD-101 due to cardiac observations, causing a 56.2% stock drop. Subsequently, on May 14, 2026, the United States — Food and Drug Administration placed a full clinical hold on MiNK Therapeutics' investigational new drug application for ARD-101, leading to another 32.1% decline in stock price. The investigation by Pomerantz LLP focuses on whether MiNK Therapeutics and its officers engaged in unlawful business practices.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard